Pepscan Blog
Notes from the lab.
Long-form writing on peptides, AI imaging, and what we're learning building PepScan.
Semaglutide: What it actually does to your body
Past the Ozempic headlines. How a GLP-1 agonist quiets hunger, what the trials really show, and what most people get wrong about it.
By PepScan Team
Retatrutide: The triple agonist outperforming Semaglutide
Lilly's investigational triple agonist hits three receptors at once. The phase 2 numbers are doing things the field has not seen.
By PepScan Team
BPC-157: What the research really says
The biohacker forums treat it as a wonder peptide. The clinical literature treats it as an open question. Both are correct in different ways.
By PepScan Team
GHK-Cu: The copper peptide behind half of high-end skincare
It shows up in serums that cost more per ounce than gold. The premium has more to do with collagen biology than with copper.
By PepScan Team
MK-677: The oral that acts like growth hormone
It is a pill. It raises growth hormone. The catch is in the side effect profile, not the convenience.
By PepScan Team
Melanotan II: The tanning peptide with a catch
It does what it says. The catch is that it does several other things too, and one of them shows up on a dermatology referral.
By PepScan Team
PTD-DBM: The Wnt-pathway approach to hair regrowth
Most hair-loss treatments target hormones. This one targets the signaling pathway your follicles use to decide whether to keep growing.
By PepScan Team